Dive Brief:

摘要：

French drugmaker Sanofi agreed to pay $125 million to startup Earendil Labs for two drug candidates designed to treat autoimmune and inflammatory bowel diseases.

法国制药商赛诺菲同意支付1.25亿美元给初创公司Earendil Labs，用于购买两种旨在治疗自身免疫和炎症性肠病的候选药物。

Under the

在

terms of the deal announced Thursday

周四宣布的交易条款

, Earendil may receive as much as $1.72 billion in additional payments for reaching certain development and commercial goals, including $50 million described as a “near-term payment.” The startup will also be eligible for royalties if the drugs reach the market.

Earendil可能因为达成某些开发和商业目标而获得高达17.2亿美元的额外付款，其中包括被描述为“近期付款”的5000万美元。如果这些药物上市，该初创公司还将有资格获得专利费。

The candidates, HXN-1002 and HNX-1003, are bispecific antibodies designed to engage two different proteins in the body involved in inflammation and immune cell activation. HXN-1002 is being developed for patients with ulcerative colitis and Crohn’s disease. HXN-1003 has shown promise in preclinical models of colitis and skin inflammation, Earendil said..

候选药物 HXN-1002 和 HNX-1003 是双特异性抗体，旨在结合体内参与炎症和免疫细胞激活的两种不同蛋白质。HXN-1002 正在开发用于治疗溃疡性结肠炎和克罗恩病患者。Earendil 表示，HXN-1003 在结肠炎和皮肤炎症的临床前模型中显示出希望。

Dive Insight:

深度洞察：

Dual-targeting antibodies have drawn considerable interest from pharmaceutical companies in recent years. But while much of the early activity centered around oncology, many drugmakers of late have focused on bispecifics’ potential treating autoimmune conditions. Sanofi just last month agreed to pay .

近年来，双靶点抗体引起了制药公司的极大兴趣。虽然早期的许多研究活动集中在肿瘤学上，但近来许多制药商已将重点放在双特异性抗体治疗自身免疫性疾病的潜力上。赛诺菲就在上个月同意支付。

$600 million to Dren Bio

6亿美元投资于Dren Bio公司

for a drug it hopes can “reset” the immune system.

对于一种有望“重置”免疫系统的药物。

HXN-1002 is designed to inhibit α4β7 and TL1A, while HXN-1003 takes aim at TL1A and IL23, the latter two of which have become popular targets for drugmakers. The approved medicines

HXN-1002旨在抑制α4β7和TL1A，而HXN-1003则针对TL1A和IL23，后两者已成为制药商的热门靶点。获批药物

Tremfya, Skyrizi

特雷姆亚，斯基里兹

and

和

Ilumya

伊利姆亚

are all IL23 inhibitors. TL1A, meanwhile, is the focus of a raft of research by top drugmakers including

都是IL23抑制剂。与此同时，TL1A是包括顶级制药公司在内的众多研究的重点，

Merck & Co.

默克公司

,

，

Roche

罗氏

,

，

AbbVie

艾伯维

and a collaboration between

以及合作之间

Sanofi and Teva Pharmaceuticals

赛诺菲和梯瓦制药

.

。

Earendil gave few details about its prior research on HXN-1002 and HXN-1003 in the news release on Thursday and its website consists only of a

埃兰迪尔在周四的新闻发布中很少提及关于HXN-1002和HXN-1003的先前研究细节，其网站上也仅包含一个信息。

home page

首页

. The U.S. startup is associated with

。这家美国初创公司与

Helixon Therapeutics

螺旋松治疗学

, which is

，即

backed

支持

by a number of Chinese venture capital firms, and is part of a

由中国多家风险投资公司投资，并且是

growing biotechnology sector in China

中国不断发展的生物技术领域

that is increasingly attracting partners in the U.S.

这正日益吸引着美国的合作伙伴。

Earendil uses artificial intelligence to streamline drug discovery and speed up development. The company says it’s focused on protein-based biologics and aims to produce drugs that are either the first of their kind or the best in a particular group.

Earendil利用人工智能简化药物发现并加速开发进程。该公司表示，它专注于基于蛋白质的生物制剂，并旨在生产要么是首例要么是在特定组别中最好的药物。